Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | CALML3 | P27482 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SDHA | P31040 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1383835 | 0.96 | MAOA (0.52) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL13760400 | 0.92 | MAOA (0.52) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL1556065 | 0.89 | MAOA (0.63) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL1378263 | 0.86 | MAOA (0.59) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL13089909 | 0.85 | MAOA (0.59) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL13760401 | 0.84 | MAOA (0.62) | MAOA | |
| SCHEMBL13089916 | 0.84 | CYP3A4 (0.51) | MAOACALML3 | |
| SCHEMBL13760396 | 0.83 | MAOA (0.53) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL1393513 | 0.83 | MAOA (0.56) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL12606546 | 0.81 | CALML3 (0.49) | MAOAMAOBCALML3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-11-23 | — | — | US | disclosed |
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-02-23 | — | — | US | disclosed |
| US-9163043-B2 | Oxazolidinone derivatives | DONG-A ST CO., LTD. (KR) | 2015-10-20 | — | — | US | disclosed |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2014-11-27 | — | — | US | disclosed |
| US-20130281492-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | TRIUS THERAPEUTICS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130274174-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | TRIUS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8461188-B2 | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use | TRIUS THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102523-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | TRIUS THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8420676-B2 | Oxazolidinone derivatives | DONG-A PHARMACEUTICALS CO. LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885MAOB 1905/4885CALML3 3337/4885 |
| US-20130281492-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885MAOB 1905/4885CALML3 3337/4885 |
| US-20130102523-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | EIF4EBP1, EIF4E, EIF6 | MAOA 4539/4885MAOB 4420/4885CALML3 1972/4885 |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | MAOA 4398/4885MAOB 4248/4885CALML3 1992/4885 |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885MAOB 1905/4885CALML3 3337/4885 |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885MAOB 1905/4885CALML3 3337/4885 |
| US-20130274174-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | EIF4EBP1, EIF4E, EIF6 | MAOA 4539/4885MAOB 4420/4885CALML3 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.